Purine Derivatives and methods of use thereof

Details Purine Derivatives and methods of use thereof Purine Derivatives and methods of use thereof

2011-01-04

2011-01-04

Crane, Lawrence E (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S027230, C536S027630

Reexamination Certificate

active

07863253

ABSTRACT:
The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for treating or preventing an ischemic condition, reperfusion injury, a cellular proliferative disorder, a cardiovascular disease, a neurological disorder, a skin disorder, a radiation-induced injury, a wound, or an inflammatory disease comprising administering an effective amount of a Purine Derivative to a subject in need thereof. The Purine Derivatives include compounds of the following formula:or a pharmaceutically acceptable salt thereof,whereinA is —C(O)NHR3;B and C are —OH;D is

REFERENCES:
patent: 3832341 (1974-08-01), Duschinsky
patent: 4443836 (1984-04-01), Horiuchi et al.
patent: 4968697 (1990-11-01), Hutchison
patent: 5140015 (1992-08-01), Olsson et al.
patent: 5219840 (1993-06-01), Gadient et al.
patent: 5278150 (1994-01-01), Olsson et al.
patent: 5280015 (1994-01-01), Jacobson et al.
patent: 5443836 (1995-08-01), Downey et al.
patent: 5589467 (1996-12-01), Lau et al.
patent: 5789416 (1998-08-01), Lum et al.
patent: 6180615 (2001-01-01), Zablocki et al.
patent: 6214807 (2001-04-01), Zablocki et al.
patent: 6326359 (2001-12-01), Monaghan et al.
patent: 6368573 (2002-04-01), Leung
patent: 6403567 (2002-06-01), Zablocki et al.
patent: 6426337 (2002-07-01), Cox et al.
patent: 6440948 (2002-08-01), Zablocki et al.
patent: 6448236 (2002-09-01), Monaghan
patent: 6525032 (2003-02-01), Mantell et al.
patent: 6528494 (2003-03-01), Cox et al.
patent: 6531457 (2003-03-01), Linden et al.
patent: 6534486 (2003-03-01), Allen et al.
patent: 6638914 (2003-10-01), Fishman et al.
patent: 6753322 (2004-06-01), Mantell et al.
patent: 6921753 (2005-07-01), Mantell et al.
patent: 7238676 (2007-07-01), Mantell et al.
patent: 2001/0051612 (2001-12-01), Cristalli
patent: 2003/0013675 (2003-01-01), Yeadon et al.
patent: 2003/0055021 (2003-03-01), DeNinno et al.
patent: 2005/0282768 (2005-12-01), Jagtap et al.
patent: 2007/0238694 (2007-10-01), Salzman et al.
patent: WO-95/02604 (1995-01-01), None
patent: WO-95/11681 (1995-05-01), None
patent: WO-96/02553 (1996-02-01), None
patent: WO-97/33590 (1997-09-01), None
patent: WO-97/33879 (1997-09-01), None
patent: WO-98/50047 (1998-11-01), None
patent: WO-99/20284 (1999-04-01), None
patent: 99/34804 (1999-07-01), None
patent: WO-01/19360 (2001-03-01), None
patent: WO-02/055085 (2002-07-01), None
patent: WO-02/083152 (2002-10-01), None
Jagtap, Prakash G. et al., “2-(N-Acyl) and 2-N-acyl-N6-substituted analogues of adenosine and their affinity at the human adenosine receptors,”Bioorganic&Medicinal Chemistry Letters, vol. 14:1495-1498 (2004).
International Search Report for Application No. PCT/US05/33476, dated Jan. 2, 2008.
Al-Mughales et al., “The chemoattractant activity of rheumatoid synovial fluid for human lymphocytes is due to multiple cytokines.”Clin. Exp. Immunol., 1996, vol. 106, pp. 230-236.
Baraldi et al.,“Synthesis and Biological Activity of a New Series of N6-Arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, andN6-Carboxamido Derivatives of Adenosine-5'-N-ethyluronamide as A1and A3Adenosine Receptor Agonists”J. Med. Chem., 1998, vol. 41, pp. 3174-3185.
Beukers et al., “New, Non-Adenosine, High-Potency Agonists for the Human Adenosine A2BReceptor with an Improved Selectivity Profile Compared to the Reference AgonistN-Ethylcarboxamidoadenosine”J. Med. Chem., 2004, vol. 47, pp. 3707-3709.
Beukers, et al., “N6-Cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl)adenosine (TCPA), a Very Selective Agonist with High Affinity for the Human Adenosine A1Receptor.”J. Med. Chem., 2003, 46:1492-1503.
Bouma et al. “Differential Regulatory Effects of Adenosine on Cytokine Release by Activated Human Monocytes.”J. Immunol., 1994, vol. 153, pp. 4159-4168.
Bradley et al., “Purine Nucleoside-Dependent Inhibition of Cellular Proliferation in 1321N1 Human Astrocytoma Cells.”J. Pharmacol. Expt. Ther., 2001, vol. 299, pp. 748-752.
Camaioni, et al., “Adenosine receptor agonists: Synthesis and biological evaluation of the diastereoisomers of 2-(3-hydroxy-3-phenyl-1-propyn-1-yl)NECA.”Bioorg. Med. Chem., 1997, 5(12):2267-2275.
Cristalli et al., “2-Alkynyl Derivatives of Adenosine and Adenosine-5'-N-ethyluronamide as Selective Agonists a A2Adenosine Receptors”J. Med Chem, 1992, vol. 35, pp. 2363-2368.
Cristalli et at., “2-Alkynyl Derivatives of Adenosine-5'-N-ethyluronamide: Selective A2Adenosine Receptor Agonists with Potent Inhibitory Activity on Platelet Aggregation.”J. Med. Chem., 1994, vol. 37, pp. 1720-1726.
Cristalli et al., “2-Aralkynyl and 2-Heteroalkynyl Derivatives of Adenosine-5'-N-ethyluronamide as Selective A2aAdenosine Receptor Agonists.”J. Med. Chem., 1995, vol. 38, pp. 1462-1472.
Dalpiaz, et al., “Synthesis and Study of 5'-Ester Prodrugs of N6-Cyclopentyladenosine, a Selective A1 Receptor Agonist.”Pharm. Res., 2001, 18(4):531-536.
De Lean, et al., “Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes.”Mol. Pharm., 1982, 21:5-16.
DeNinno et al., “3'-Aminoadenosine-5'-uronamides: Discovery of the First Highly Selective Agonist at the Human Adenosine A3Receptor”J. Med. Chem., 2003, vol. 46, pp. 353-355.
Fisher et al., “Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion Protein”N. Engl. J. Med., 1996, vol. 334, pp. 1697-1702.
Francis et al., “Highly Selective Adenosine A2Receptor Agonists in a Series of N-Alkylated 2- Aminoadenosines”J. Med. Chem., 1991, vol. 34, pp. 2570-2579.
Hasko et al. “Adenosine Receptor Agonists Differentially Regulate IL-10, TNF-α, and Nitric Oxide Production in RAW 264.7 Macrophages and in Endotoxemic Mice.”J. Immunol., 1996, vol. 157, pp. 4634-4640.
Homma et al., “Nucleosides and Nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: A New Entry of Selective A2Adenosine Receptor Agonists with Potent Antihypertensive Activity”J. Med. Chem., 1992, vol. 35, pp. 2881-2890.
Hutchison et al., “2-(Arylalkylamino)adenosin-5'-uronamides: A New Class of Highly Selective Adenosine A2Receptor Ligands”J. Med. Chem., 1990, vol. 33, pp. 1919-1924.
Klotz et al., “Comparative pharmacology of human adenosine receptor subtypes—characterization of stably transfected receptors in CHO cells.”Naunyn-Schmiedeberg's Arch. Pharmacol., 1998, vol. 357, pp. 1-9.
Klotz et al., “Photoaffinity Labeling of A1-adenosine Receptors”J. Biol. Chem., 1985, vol. 260, pp. 14659-14664.
Kunkel et al.., “The role of chemokines in inflammatory joint disease”J. Leukocyte Biol., 1996, vol. 59, pp. 6-12.
Lichtenthaler, et al., “Nucleosides, XVIII1. Improved Preparation of Nucleoside 5'-Nitrates.”Synthesis, 1974, 199-201.
Lohse et al., “8-Cyclopentyl-1,3-dipropylxanthine (DPCPX)—a selective high affinity antagonist radioligand for A1adenosine receptors”Naunyn-Schmiedeberg's Arch. Pharmacol., 1987, vol. 336, pp. 204-210.
Mager et al., “Molecular simulation applied to 2-(N′-alkylidenehydrazino)- and 2-(N′aralkylidenehydrazino)adenosine A2agonists”Eur. J. Med. Chem., 1995, vol. 30, pp. 15-25.
Matsuda et al., “Nucleosides and Nucleotides. 103. 2- Alkynyladenosines: A Novel Class of Selective Adenosine A2Receptor Agonists with Potent Antihypertensive Effects.”J.Med. Chem., 1992, vol. 35, pp. 241-252.
McWhinney et al., “Activation of adenosine A3receptors on macrophages inhibits tumor necrosis factor-α”Eur. J. Pharmacol., 1996, vol. 310, pp. 209-216.
Moos, et al., “N6-cycloalkyladenosines. Potent, A1-selective adenosine agonists.”J. Med. Chem., 1985, 28(10):1383-1384.
Muller, “Adenosine Receptor Ligands-Recent Developments Part I. Agonists.”Current Medicinal Chem

Affiliated with

Also associated with

Rating

Purine Derivatives and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Purine Derivatives and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purine Derivatives and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2667309